Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects With A Urea Cycle Disorder With Inadequate Control on Standard of Care

NCT03933410 is registered in ClinicalTrials.gov with Kaleido Biosciences as lead sponsor.

NCT NCT03933410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03933410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects With A Urea Cycle Disorder With Inadequate Control on Standard of Care
Lead sponsor
Kaleido Biosciences
Phase
Phase 2
Overall status
Terminated
Start date
September 17, 2019
Completion date
March 2, 2021
Enrollment
13 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

urea cycle disorder